pembrolizumab,nivolumab,ipilimumab
merck,bms
['cm 914', 'rcc,(-irccs),(-srcc),(-urcc)', 'kn-564']
why the difference between cm 914 and kn-564? dr. j larkin in rcc we still do not have clinically usable molecular markers for treatment selection! #esmo22 
Pursuing to improve cancer prevention and care. Medical Oncologist @AnkaraUni